ACC Latin America 2022 Together with CardioAcademic Focuses on Global Collaboration

The American College of Cardiology and CardioAcademic will host ACC Latin America 2022 Together with CardioAcademic in Mexico City from September 10-11, 2022. The event will bring the Latin American cardiology community together to examine emerging trends and evidence-based strategies for the prevention and management of cardiovascular disease, as well as present exciting new research being done in the region.

ACC Vice President B. Hadley Wilson, MD, FACC, executive vice-chair at the Sanger Heart & Vascular Institute, and ACC Assembly of International Governors Past Chair Erick Alexanderson, MD, FACC, chairman of the Nuclear Cardiology Department at the Instituto Nacional de Cardiología “Ignacio Chávez” and director of CardioAcademic, will serve as co-chairs for the conference.

“ACC‘s vision is a world where science knowledge and innovation optimize cardiovascular care and outcomes and what better way than getting together at ACC Latin America regional conference paired with CardioAcademic in Mexico City,” Wilson said. “These are two great meeting venues joined together for the best Latin America regional conference with cardiovascular thought leaders, along with other leaders in the Americas creating a dynamic exchange of leading-edge knowledge and practical networking. We’re sure attendees will find plenty to take home and put into practice for their patients.”

Valentin Fuster, MD, PhD, MACC, editor-in-chief of the Journal of the American College of Cardiology, will present the Opening Plenary Session, “New Frontiers in Cardiovascular Health: From the Heart to the Brain.” Other key sessions will examine the top cardiovascular complications of COVID-19, beginning primary prevention of heart disease through childhood education and the care of cardio-oncology patients. In addition to in-person sessions, the conference will feature a hybrid option with attendees having access to all virtual content.

Learn more about the conference at ACC.org/LatinAmerica2022.

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”